On Oct. 6, 2020, Pfizer and BioNTech announced initiation of a rolling submission to the European Medicines Agency (EMA) for BNT162b2, the lead candidate from the companiesﾒ vaccine development program against COVID-19. As part of the rolling review, the CHMP began evaluating data generated in pre-clinical trials.